Disclosed are piperidinylamino pyridazine compounds of formula I where the variables are described in the disclosure. The compounds a suitable for use as dopamine 2 receptor antagonists and antipsychotics. Also disclosed is the process for making compounds of formula I and the use of the compounds in making a medicatment to treat a number of antipsychotic disorders such asschizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder, psychotic disorder not otherwise specified, psychosis associated with dementia, major depressive disorder, dysthymic disorder, premenstrual dysphoric disorder, depressive disorder not otherwise specified, Bipolar I disorder, bipolar II disorder, cyclothymic disorder, bipolar disorder not otherwise specified, mood disorder due to a general medical condition, substance-induced mood disorder, mood disorder not otherwise specified, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, acute stress disorder, post-traumatic stress disorder, mental retardation, pervasive developmental disorders, attention deficit disorders, attention-deficit/hyperactivity disorder, disruptive behaviour disorders, personality disorder of the paranoid type, personality disorder of the schizoid type, personality disorder of the schizotypical type, tic disorders, Tourette's syndrome, substance dependence, substance abuse, substance withdrawal, trichotillomania.
PIPERIDINYLAMINO-PYRIDAZINES AND THEIR USE AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS